GlaxoSmithKline P.L.C., a British pharmaceutical company which manufactures the antidepressant Paxil and controversial diabetes pill Avandia is expected to record a legal charge of $2.4 billion for the second quarter of this fiscal year in order to settle legal cases regarding the drugs. GlaxoSmithKline P.L.C. said the money would be used to cover the settlements for Avandia, an investigation into a former factory in Cidra, Puerto Rico , and other long-standing legal cases.
“Some people might baulk at the size of the charge but probably most will say this is putting it all behind the company, so we can now look to the continuing business and view the stock on a more rational basis,” said Deutsche Bank analyst Mark Clark.
The charge, which is 2.5 percent of the total market value of GlaxoSmithKline P.L.C. slowed the rise of shares after a United States panel allowed the company to sell Avandia, with a warning on heart risks included on the bottle.
GlaxoSmithKline P.L.C. would not release information on the terms of settlement regarding Avandia cases stating that the information is confidential. It was reported that GlaxoSmithKline P.L.C. could spend $6 billion on cases related to Avandia. The panel vote to keep the drug in market meaens the company would be able to settle the claims for $1 billion.
“This represents a substantial proportion of GSK’s outstanding litigation. This progress is helping us to reduce financial uncertainty and risk for shareholders,” Dan Troy, the drug maker’s general counsel, said in a statement.
GlaxoSmithKline P.L.C. stated the company is resolving the disputes to avoid possible legal complications.
